You are here

IGF OT IGF PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 261201600027C-0-0-0
Agency Tracking Number: N43CA160027
Amount: $299,502.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1 RESEARCH CT, STE 450
ROCKVILLE, MD 20850-6252
United States
DUNS: 078720415
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MIGUEL DIAZ
 (204) 271-0641
 dritscha@georgetown.edu
Business Contact
 MIGUEL DIAZ
Phone: (204) 271-0641
Email: dritscha@georgetown.edu
Research Institution
N/A
Abstract

Patients treated for prostate cancer may experience treatment related late effects thatadversely affect quality of life and may prove life threatening The objective of this Phase I SBIRapplication is to determine the technical and commercial feasibility of a biomarker panelpredictive of radiation mediated late effects in patients treated for prostate cancer We willdevelop a metabolite signature of radiation responses in a cohort of patients undergoingstereotactic body radiation therapy SBRT for prostate cancer Analysis of banked plasmasamples will be correlated with clinical outcomes to identify markers of urinary andgastrointestinal late effects for validation in a larger clinical population to be proposed in asubsequent Phase II application The Phase II effort will allow Shuttle Pharmaceuticals toadvance its proposed commercialization plan and to raise capital to support validation clinicaltrials leading to FDA approval Patients treated with stereotactic body radiation therapy SBRT for prostate cancers onan IRB approved protocol have banked clinical specimens and detailed monitoring of quality oflife parameters Sub sets of these patients have developed urinary incontinence UI symptomatic urinary flare USF obstructed voiding symptoms retention UR and radiationproctitis RP We have used high resolution mass spectrometry based metabolomics lipidomicprofiling to analyze this unique cohort of patient samples and propose here to leverage ourestablished analytical platform to advance product development and validation of a biomarkerpanel predictive of radiation toxicities Metabolites in plasma from a cohort of de identifiedpatients will be analyzed to develop a kit supporting metabolomic analysis to serve as abiomarker panel predictive of patient susceptibility for radiation late effects

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government